Neogen CORP 8-K filings

Neogen Corporation announced the resignation of a director from its Board.

Neogen Corporation announced its fiscal year 2026 fourth quarter and full fiscal year results, highlighting strong core growth in Food Safety and providing financial guidance for fiscal year 2027.

Neogen Corporation is hosting investor tours of its Petrifilm facility and has completed operational qualifications for certain Petrifilm SKUs.

Neogen Corporation announced third quarter fiscal year 2026 financial results, reporting a revenue decrease of 4.4% to $211.2 million, while also revealing the divestiture of its Genomics business for $160 million.

Neogen Corporation announced that its Chief Legal and Administrative Officer, Amy Rocklin, will leave the company effective March 31, 2026.

Neogen Corporation reported second-quarter fiscal 2026 results, showing a 2.8% revenue decrease year-over-year but a 2.9% core revenue increase, and raised its full-year 2026 revenue and Adjusted EBITDA guidance.

Neogen Corporation announced the appointment of Bryan Riggsbee, a seasoned financial leader from bioMérieux and Myriad Genetics, as its new Senior Vice President and Chief Financial Officer, effective November 3, 2025.

Neogen Corporation announced that newly appointed director Avi Pelossof will serve on the Audit and Compensation and Talent Management Committees, effective October 24, 2025.

Neogen Corporation filed an amended 8-K to correct an error, confirming shareholders approved executive compensation at the October 23, 2025 Annual Meeting.

Neogen Corporation's shareholders voted against the compensation of named executive officers at the 2025 Annual Meeting, while re-electing directors and ratifying auditors.

Neogen Corporation announced first-quarter fiscal 2026 results, reporting a revenue decline and lower adjusted profitability, alongside a new CEO and restructuring efforts.

Neogen Corporation announced the resignation of Chief Financial Officer and Chief Operating Officer David Naemura, with a transition plan in place until year-end.

Neogen Corporation announced a significant shift in its executive long-term incentive compensation for fiscal year 2026, introducing Performance Share Units tied to key financial metrics and relative shareholder return.

Neogen Corporation announced a significant board transition with the retirement of long-serving director William Boehm and the appointment of diagnostics industry veteran Avi Pelossof.

Neogen Corporation announced a significant fourth-quarter net loss of $612.2 million, primarily due to a non-cash goodwill impairment charge, alongside declining revenues and persistent end-market challenges.

Neogen Corporation announced the appointment of Mikhael Nassif, formerly of Siemens Healthineers, as its new President and Chief Executive Officer, effective August 11, 2025.

Neogen Corporation presented an investor update outlining its strategic focus on food safety, the ongoing integration of the 3M Food Safety business, preliminary Q4 FY25 financial expectations, and a comprehensive improvement plan.

Neogen Corporation provides updates on its improvement plan, including growth acceleration, margin expansion, portfolio optimization, leverage reduction, and governance enhancements, while also addressing the impact of tariffs on Adjusted EBITDA.

Neogen Corporation announces the retirement of James P. Tobin from its Board of Directors and the appointment of Andrea Wainer, effective June 1, 2025.

Neogen Corporation provides an update on its Petrifilm product line, including the transition of manufacturing to a new facility in Lansing, Michigan.

Neogen Corporation announces that CEO and President John Adent will step down, with the Board of Directors forming a special committee to find a replacement.

Neogen Corporation announces its third-quarter 2025 results, reporting revenue of $221.0 million and updating its full-year guidance due to lower-than-expected results and macroeconomic uncertainty.

Neogen successfully refinanced its term loan and revolving credit facility, extending the maturity to April 2030 and achieving a lower interest rate.

Neogen Corporation announced preliminary second-quarter results for fiscal year 2025, showing revenue growth but a significant net loss due to a non-cash goodwill impairment.

Neogen Corporation has appointed David Naemura as Chief Operating Officer, effective January 1, 2025, while Doug Jones will retire as COO on February 28, 2025, and transition to a part-time role.

Neogen Corporation has updated its previous 8-K filing to include the committee assignments for newly appointed director, Thierry Bernard.

Neogen Corporation presented at the Piper Sandler Healthcare Conference, highlighting its position as a leader in food and animal safety and outlining its growth strategy.

Neogen Corporation held its 2024 Annual Meeting of Shareholders on October 24, 2024, with key votes on director elections, executive compensation, and auditor ratification.

Neogen Corporation's Chief Operating Officer, Douglas E. Jones, plans to retire in early 2025, prompting a reorganization and the creation of a new Chief Commercial Officer role.

Neogen Corporation announced its first quarter 2025 results, showing a revenue decrease and a net loss, but maintains its full-year guidance.